Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Milestones still hang
In June 2005, we entered into an acquisition agreement with Cephalon, Inc., or Cephalon, pursuant to which we divested the compound,
TRISENOX. Cephalon was subsequently acquired by Teva Pharmaceutical Industries Ltd., or Teva. Under this agreement, we have the right to receive up
to $100 million in payments upon achievement by Teva of specified sales and development milestones related to TRISENOX. To date, we have received
$60.0 million of such potential milestone payments as a result of having achieved certain sales milestones.
time is short but the need is high! Is it possible that no commercialization will be viable in the short term?
https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-enpaxiq_en.pdf
Graig, then what are you doing for Europe?
As the commercial launch of VONJOTM (pacritinib) in the U.S. continues to exceed our expectations, we are pleased to highlight VONJO's clinical value as a potential best in class treatment for patients with cytopenic myelofibrosis with platelet counts below 50 × 109/L.
another opportunity to return!
unbelivable
I don't know whether to wait for them to let off steam a little longer before returning
maybe next week
I am tempted
This risk-adjusted analysis demonstrates that the safety profile of pacritinib 200 mg BID is comparable to BAT. In particular, rates of bleeding were not elevated on pacritinib 200 mg BID compared to BAT, both overall and in patients with PLT <50 x 109/L. Rates of fatal events, thrombosis, major adverse cardiac events (MACE) and non-melanoma skin cancer were higher on ruxolitinib than pacritinib. These results indicate that pacritinb 200 mg BID may represent a full-dose therapeutic option for patients with myelofibrosis, including those with thrombocytopenia.
good good good...
Selective inhibition of the JAK2/STAT3 axis, an IFN-?, IL-6 and IL-23 receptor signaling response element, by Pacritinib (SB1518) was also shown to significantly reduce GVHD in murine models (181, 225). Similar to the effects of the JAK/STAT3 inhibitor Fedratinib in early MLR experiments; Pacritinib, led to impaired expansion of Th1 and Th17 cells while Treg and Th2 responses were sustained (181, 182). A recent study also reported a successful combinatory therapy of acute GVHD with Pacritinib the STAT3 inhibitor S31-201 and the mTOR inhibitor Rapamycin in a xenogeneic mouse model and with Rapamycin and the calcineurin inhibitor Tacrolismus in patients (166).
https://www.frontiersin.org/articles/10.3389/fimmu.2021.806529/full
some impressive gain
https://www.fool.com/investing/2022/05/13/why-cti-biopharma-stock-is-surging-today/
Shorooooooooooooooooty!
Many kisses!
https://fintel.io/so/us/ctic
https://fintel.io/sst/us/ctic
ASC
Russell
SALES RESULT
BO
https://www.tipranks.com/news/blurbs/cti-biopharma-ctic-receives-a-buy-from-jmp-securities?utm_source=stck.pro&utm_medium=referral
they forgot zevalin and trisenox
https://www.biospace.com/article/releases/cti-biopharma-receives-10-million-milestone-payment-for-trisenox-/
https://investor.sppirx.com/news-releases/news-release-details/spectrum-pharmaceuticals-and-cell-therapeutics-jointly-market
having exceeded our internal projections with $2.5 million in net product sales in just a few weeks.
(”’)O__O(”’)
-\ '( o_o )' /-
–\ \_[ ]_/ /—Hands up!!!
—l . . . . l—
-—l . . . l—
–/ ./ – \. \–
-(,,,)__(,,,)-
Do you think it's time to sell?
mmmmm NAah
I hold
MC 500 mil
Hehehehehehehehehehe
it's almost time!
a nice handle thanks /
03/15/2022 8,316,332 19,273,272 1
02/28/2022 6,634,484 1,659,793 3.997176
02/15/2022 6,330,335 870,251 7.274148
01/31/2022 5,081,535 1,559,251 3.258959
01/14/2022 2,549,192 1,351,533 1.886149
12/31/2021 2,989,143 1,381,568 2.163587
Tic toc tic toc
ReniBenjamin
Okay. And then I guess just turning to the commercialization side. Can you just remind me, have you guys already identified the centers or the community docs that you will be targeting right off the bat? Or how should we be thinking about the initial phases of the launch?
AdamCraig
Bruce will answer.
BruceSeeley
The -- in initial launch were not surprising any target, the high volume accounts in the academic centers, and then we've identified also the large community accounts that treat quite a few patients, the group practice or the large group practices. And that's where the far majority of the patients are treated.
ReniBenjamin
And Bruce, about how many, could you give us like how many accounts are there from academic versus community?
BruceSeeley
It depends on how you look at it. Just in terms of number of physicians, the majority of physicians are going to be in the community accounts. They treat anywhere from 0, 1 or 2 patients to 5-ish patients. The large practices are the ones that we're going to be focused on. And the academic centers we're focused on, they can treat 20 to 50 patients per year depending on the site.
Operator
Your next question is from Thomas Flaten of Lake Street Capital.
ThomasFlaten
Adam, how do you -- how should we think about PACIFICA enrollment once you guys go live commercially? Do you see there being some cannibalization there or have you -- do you have a strategy for segregating patients in the study versus commercial product?
AdamCraig
Thank you. Its a very important question. The - its most likely that PACIFICA will continue ex-U.S. after approval. And we are no doubt towards the end of the NDA process where we'll have some discussions with the FDA around the program -- around that trial with maybe some changes to it. But big picture, I don't expect that to be cannibalization of U.S. sales opportunities. The drug is performing very well ex-U.S. at the moment, and I think we could successfully complete the trial outside the U.S. on time.
the withdrawal of Russian troops from the Ukrainian capital has begun!
It seems that the thaw has begun in every sense!
Good!
I would feel bad being a shorts here!
For real!
Do you know why the price of gas has gone up so much? Only for speculators who had bet on the downside!
CTIC is a bonbon!
For example pfizer is full of money!
CLLS ALLO...
Cancer Drug... Allo-SCT... GVHD...
Golden Cross
Robocop
So, let me think!
Does the funds sling inside? Or does we fall?
We have an endorsement that Robocop (and if he says so I would not underestimate it) says it will bring us 3 bil in 2026!
Then there is the GVHD speech!
In a while we will have a taste of sales...
In June Russel
In September, or thereabouts, we'll know more about the bomb... I mean allo-SCT
And in the meantime the sales to go up...IMO
I hold ya
NEW HIT
https://clinicaltrials.gov/ct2/show/NCT03645824?cond=Pacritinib&draw=2&rank=8
Despite recent new therapeutic options, allogeneic Stem Cell Transplantation remains the only curative option in patients with Myelofibrosis. Therefore, optimalization of this therapy remains a major challenge. Improvement of the clinical condition of these patients, decreasing spleen size can be accomplished by JAK2 inhibitor treatment and might improve SCT outcome. In addition, selective JAK2 inhibitors might modulate GvHD which can also add to improved SCT outcome. Also, decreasing the burden/activity of the disease before allo-SCT might also improve final disease response. The first, limited, clinical data of ruxolitinib treatment before allo-SCT show controversial effects on the outcome of SCT. Therefore, additional prospective clinical trials have to be done to establish the role of JAK2 inhibition before allogeneic SCT. Since ruxolitinib has considerable myelosuppressive effects which might limit the clinical use in some MF patients, other selective JAK2 inhibitors might be useful in this setting. Pacritinib, as a JAK2/FLT3 inhibitor, has a very potent JAK2 inhibitory activity without myelosuppressive effects and might therefore be more suitable than ruxolitinib. The major possible side effects are gastro-intestinal and can be managed with medication. In several studies, pacritinib has shown to be effective in decreasing spleen size and has shown to improve clinical condition of patients. Therefore, this compound seems promising in improving the outcome of allo-SCT. Although pacritinib causes no inhibition of JAK1 activity and therefore might have limited effects in decreasing inflammatory response, this might also be of benefit since a "withdrawal syndrome" as has been described after cessation of ruxolitinib is not to be expected.
I wouldn't be surprised by a takeover here!
MC 400/450 mill are peanuts
Followers
|
203
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
7234
|
Created
|
09/27/05
|
Type
|
Free
|
Moderators |
| |
| |
06/03/2009 Cell Therapeutics Says Brown Uty. Study Reveals High Pathological Complete Response Rate for OPAXIO Treatment in Esophagus Cancer - Update http://www.rttnews.com/ArticleView.aspx?Id=968824&Category=Breaking%20News
http://ih.advfn.com/p.php?pid=nmona&cb=1244008008&article=38033450&symbol=N%5ECTIC http://www.tradingmarkets.com/.site/news/Stock%20News/2358071/
RAiDAR alerts Learn More About RAiDAR-LT |
company profile |
The Company focuses on the development, acquisition and commercialization of drugs for the treatment of cancer. ... MORE INFO CONTACT: Dr. James A. Bianco, M.D. (CEO) | Cell Therapeutics Inc 501 Elliott Avenue West Suite 400 Seattle, WA 98119 P: (206) 282-7100 P: (800) 215-CELL (US) F: (206) 284-6206 Company Home Page | Email |
Industry: Drugs SIC: 2834 Employees: 194 Locations: 4 State of Inc: WASHINGTON 1991 Development Stage? N | Transfer Agent: Computershare Investor Services Chicago, IL 60690 Investor Relations: Company | Authorized Shares: Unknown Source: 10-Q ( 06/30/2008 ) Outstanding Shares: 455,394,374 Source : April 30 , 2009 8K Fiscal Year End: December 31 |
CHART BY DART 1961
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |